Activity of Gefitinib in a Non-Small-Cell Lung Cancer Patient with Both Activating and Resistance EGFR Mutations

被引：13
|
作者：
Morabito, Alessandro [1 ]
Costanzo, Raffaele [1 ]
Rachiglio, Anna Maria [2 ]
Pasquale, Raffaella [2 ]
Sandomenico, Claudia [1 ]
Franco, Renato [3 ]
Montanino, Agnese [1 ]
De Lutio, Elisabetta
Rocco, Gaetano [3 ]
Normanno, Nicola [2 ,3 ]
机构：
[1] Natl Canc Inst, Med Oncol Unit, Thoracopulm Dept, I-80131 Naples, Italy
[2] Ctr Ric Oncol Mercogliano, Mercogliano, AV, Italy
[3] Natl Canc Inst, Thoracopulm Dept, I-80131 Naples, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷 / 07期
关键词：
D O I：
10.1097/JTO.0b013e318286cc26
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E59 / E60
页数：2
相关论文
共 50 条
  • [1] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Kobayashi, S
    Boggon, TJ
    Dayaram, T
    Janne, PA
    Kocher, O
    Meyerson, M
    Johnson, BE
    Eck, MJ
    Tenen, DG
    Halmos, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08): : 786 - 792
  • [2] EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer
    Giaccone, G
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (06): : 296 - 297
  • [3] EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer
    Giuseppe Giaccone
    [J]. Nature Clinical Practice Oncology, 2005, 2 : 296 - 297
  • [4] Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
    Wang, Jun
    Wang, Baocheng
    Chu, Huili
    Yao, Yunfeng
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 3711 - 3726
  • [5] EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer
    Shih, JY
    Gow, CH
    Yang, PC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02): : 207 - 208
  • [6] EGFR mutations in non-small-cell lung cancer
    Hung, Jung-Jyh
    Jeng, Wen-Juei
    Hsu, Wen-Hu
    Liu, Jung-Sen
    Wu, Yu-Chung
    [J]. LANCET ONCOLOGY, 2010, 11 (05): : 412 - 413
  • [7] Effect of EGFR mutations on gefitinib in advanced previous treated non-small-cell lung cancer
    Guo, J.
    Zhou, C.
    Deng, Q.
    Ren, S.
    Zhang, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    Gazdar, A. F.
    [J]. ONCOGENE, 2009, 28 : S24 - S31
  • [9] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    A F Gazdar
    [J]. Oncogene, 2009, 28 : S24 - S31
  • [10] Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations
    Yano, S.
    Wang, W.
    Li, Q.
    Yamada, T.
    Matsumoto, K.
    Mitsudomi, T.
    Yatabe, Y.
    Hanibuchi, M.
    Nishioka, Y.
    Sone, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345